Neuroprotective Effects of Cilomilast and Chlorogenic Acid Against Scopolamine-Induced Memory Deficits via Modulation of the cAMP/PKA–CREB–BDNF Pathway DOI Open Access
Esraa M. Mosalam,

Soha Mohamed Atya,

Noha M. Mesbah

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3108 - 3108

Опубликована: Март 28, 2025

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive decline, neuroinflammation and neuronal damage. This study aimed to investigate the neuroprotective effects of cilomilast (CILO), phosphodiesterase-4 (PDE4) inhibitor, alone in combination with chlorogenic acid (CGA), natural polyphenol, against scopolamine (SCOP)-induced impairment mice. Forty male albino mice were divided into five groups: normal control, SCOP CGA + SCOP, CILO SCOP. Behavioral assessments, including Y-maze pole climbing tests, demonstrated that significantly impaired cognition, while treatment reversed these deficits, group showing greatest improvement. Histopathological analyses revealed reduced damage amyloid beta (Aβ) accumulation. Immunohistochemical biochemical assessments confirmed decrease neuroinflammatory markers, tumor necrosis factor-alpha (TNF-α) nuclear factor kappa B (NF-κB). Molecular showed restored cyclic adenosine monophosphate (cAMP) levels, leading activation protein kinase A (PKA), cAMP response element-binding (CREB) brain-derived neurotrophic (BDNF), key regulators plasticity survival. enhanced further inhibiting PDE4, amplifying response. These findings suggest PDE4 inhibitors, particularly CGA, may represent promising therapeutic strategies for AD-related impairment.

Язык: Английский

Neuroprotective Effects of Cilomilast and Chlorogenic Acid Against Scopolamine-Induced Memory Deficits via Modulation of the cAMP/PKA–CREB–BDNF Pathway DOI Open Access
Esraa M. Mosalam,

Soha Mohamed Atya,

Noha M. Mesbah

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3108 - 3108

Опубликована: Март 28, 2025

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive decline, neuroinflammation and neuronal damage. This study aimed to investigate the neuroprotective effects of cilomilast (CILO), phosphodiesterase-4 (PDE4) inhibitor, alone in combination with chlorogenic acid (CGA), natural polyphenol, against scopolamine (SCOP)-induced impairment mice. Forty male albino mice were divided into five groups: normal control, SCOP CGA + SCOP, CILO SCOP. Behavioral assessments, including Y-maze pole climbing tests, demonstrated that significantly impaired cognition, while treatment reversed these deficits, group showing greatest improvement. Histopathological analyses revealed reduced damage amyloid beta (Aβ) accumulation. Immunohistochemical biochemical assessments confirmed decrease neuroinflammatory markers, tumor necrosis factor-alpha (TNF-α) nuclear factor kappa B (NF-κB). Molecular showed restored cyclic adenosine monophosphate (cAMP) levels, leading activation protein kinase A (PKA), cAMP response element-binding (CREB) brain-derived neurotrophic (BDNF), key regulators plasticity survival. enhanced further inhibiting PDE4, amplifying response. These findings suggest PDE4 inhibitors, particularly CGA, may represent promising therapeutic strategies for AD-related impairment.

Язык: Английский

Процитировано

0